Literature DB >> 33441565

A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis.

Shuai Zhao1,2,3, Run Tian1,2, Jun Wu4, Shaoli Liu1,2, Yuanning Wang1, Meng Wen4, Yingxu Shang1,2, Qing Liu1, Yan Li1, Ying Guo5, Zhaoran Wang1,2, Ting Wang1, Yujing Zhao4, Huiru Zhao4, Hui Cao4, Yu Su4, Jiashu Sun1,2, Qiao Jiang6,7, Baoquan Ding8,9,10.   

Abstract

Effective and safe hemodialysis is essential for patients with acute kidney injury and chronic renal failures. However, the development of effective anticoagulant agents with safe antidotes for use during hemodialysis has proven challenging. Here, we describe DNA origami-based assemblies that enable the inhibition of thrombin activity and thrombus formation. Two different thrombin-binding aptamers decorated DNA origami initiates protein recognition and inhibition, exhibiting enhanced anticoagulation in human plasma, fresh whole blood and a murine model. In a dialyzer-containing extracorporeal circuit that mimicked clinical hemodialysis, the origami-based aptamer nanoarray effectively prevented thrombosis formation. Oligonucleotides containing sequences complementary to the thrombin-binding aptamers can efficiently neutralize the anticoagulant effects. The nanoarray is safe and immunologically inert in healthy mice, eliciting no detectable changes in liver and kidney functions or serum cytokine concentration. This DNA origami-based nanoagent represents a promising anticoagulant platform for the hemodialysis treatment of renal diseases.

Entities:  

Year:  2021        PMID: 33441565     DOI: 10.1038/s41467-020-20638-7

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  7 in total

1.  A Long-Circulating Vector for Aptamers Based upon Polyphosphodiester-Backboned Molecular Brushes.

Authors:  Yuyan Wang; Dali Wang; Jiachen Lin; Zidi Lyu; Peiru Chen; Tingyu Sun; Chenyang Xue; Mehrnaz Mojtabavi; Armin Vedadghavami; Zheyu Zhang; Ruimeng Wang; Lei Zhang; Christopher Park; Gyu Seong Heo; Yongjian Liu; Sijia S Dong; Ke Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2022-09-06       Impact factor: 16.823

2.  Innovative developments and emerging technologies in RNA therapeutics.

Authors:  François Halloy; Annabelle Biscans; Katherine E Bujold; Alexandre Debacker; Alyssa C Hill; Aurélie Lacroix; Olivia Luige; Roger Strömberg; Linda Sundstrom; Jörg Vogel; Alice Ghidini
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.652

Review 3.  Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.

Authors:  Kirill A Afonin; Marina A Dobrovolskaia; Weina Ke; Piotr Grodzinski; Mark Bathe
Journal:  Adv Drug Deliv Rev       Date:  2021-12-13       Impact factor: 17.873

4.  Salting-Out of DNA Origami Nanostructures by Ammonium Sulfate.

Authors:  Marcel Hanke; Niklas Hansen; Ruiping Chen; Guido Grundmeier; Karim Fahmy; Adrian Keller
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

Review 5.  Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney.

Authors:  Qiaohui Chen; Yayun Nan; Yuqi Yang; Zuoxiu Xiao; Min Liu; Jia Huang; Yuting Xiang; Xingyu Long; Tianjiao Zhao; Xiaoyuan Wang; Qiong Huang; Kelong Ai
Journal:  Bioact Mater       Date:  2022-09-29

6.  Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.

Authors:  Haibin Wu; Liyu Zhang; Zeen Zhu; Chenxi Ding; Shengquan Chen; Ruiping Liu; Huafeng Fan; Yang Chen; Hui Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

7.  CRISPR-Cas9-mediated nuclear transport and genomic integration of nanostructured genes in human primary cells.

Authors:  Enrique Lin-Shiao; Wolfgang G Pfeifer; Brian R Shy; Mohammad Saffari Doost; Evelyn Chen; Vivasvan S Vykunta; Jennifer R Hamilton; Elizabeth C Stahl; Diana M Lopez; Cindy R Sandoval Espinoza; Alexander E Deyanov; Rachel J Lew; Michael G Poirer; Alexander Marson; Carlos E Castro; Jennifer A Doudna
Journal:  Nucleic Acids Res       Date:  2022-02-22       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.